MET and liver cancer: Western blotting verified that the combination treatment of Cabozantinib and IL-32γ overexpression significantly decreased the mTOR-related proteins (p-mTOR, p-4E-BP1, and p-S6 kinase) and MET but increased p-ULK1 in the liver cancer cell lines (Figure 4E).